Effect of Exercise on Premature Ejaculation

Status Completed

Clinical Trial Summary

Premature ejaculation (PE) is one of the prevalent disorders in men; its leading sequel such as lack of self-confidence, anxiety, depression and unsatisfactory intercourse in men and their partners. The current study was aimed to evaluate the relationship between ejaculation and physical activity.

Clinical Trial Description

Premature ejaculation (PE) is the most frequent sexual dysfunction in males, and its prevalence has been reported as 21-33%. Currently, there are no universal criteria for the diagnosis, or treatment strategies or approaches for PE. Lack of observational studies directed to PE makes comprehension of this sexual dysfunction difficult. The common point for definition of PE is a short duration between penetration and ejaculation, little or no control on voluntary control of ejaculation, and annoying character and negative effect of this condition on the individual. There are various treatment methods since ejaculation physiology and neuroanatomy is not yet clearly demonstrated. According to neurobiological hypothesis of Waldinger, a dysfunction in the serotonin pathway of the central system such as serotonin-2C hyposensitivity and/or serotonin-1A receptor hypersensitivity is a possible cause of lifelong PE. These experimental animal models showed that serotonergic activity at hypothalamic level inhibited ejaculation reflex. Based on this physiological effect, selective serotonin reuptake inhibitors (SSRI), and serotonin agonists increase intravaginal ejaculation latency time (IELT). A number of studies showed that exercise increased the functional effect of serotonin in the human brain.

The effects of physical activity level on human health have attracted interest worldwide. Lack of physical activity forms the basis of various health problems, however regular physical act contributes prevention and treatment of a number of disorders.

In current study, investigators will compare the ejaculation control, IELT, and prevalence of PE between sportsmen that have regular physical activity, and the individuals with a sedentary lifestyle. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02984592
Study type	Observational [Patient Registry]
Source	Ankara Training and Research Hospital
Contact
Status	Completed
Phase	N/A
Start date	November 2016
Completion date	January 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02232425` - IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)	Phase 2
Completed	`NCT01439984` - Trial of PED-1 in Male Patients With Premature Ejaculation	Phase 3
Completed	`NCT01184105` - A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation	Phase 1
Completed	`NCT01203202` - Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation	Phase 2
Completed	`NCT03942367` - Evaluation of the Safety and Effectiveness of the vPatch Device	N/A
Recruiting	`NCT06425211` - Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.	N/A
Completed	`NCT02939495` - The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy	Phase 4
Completed	`NCT02572037` - Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research
Recruiting	`NCT02581826` - Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation	Phase 2
Terminated	`NCT00983736` - Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation	Phase 3
Completed	`NCT00549211` - A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.	Phase 1
Completed	`NCT00556478` - Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation	Phase 2/Phase 3
Not yet recruiting	`NCT05556083` - Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)	Phase 2
Completed	`NCT03304808` - Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0	N/A
Completed	`NCT00861484` - Proof of Mechanism in ELT	Phase 1
Recruiting	`NCT02571101` - A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation	Phase 2
Completed	`NCT03174470` - Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle	N/A
Completed	`NCT02794454` - A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health	N/A
Completed	`NCT02297152` - A New Treatment for Premature Ejaculation?	N/A
Not yet recruiting	`NCT00656552` - Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation	Phase 0

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.